Edgeworth’s experts have deep experience analyzing economic issues in the pharmaceutical industry in the areas of antitrust, intellectual property, commercial damages, and consumer protection. Since our founding in 2009, Edgeworth’s economists have served as both testifying and consulting economists on a wide array of industry-specific matters before courts and regulatory authorities.
Our pharmaceutical economics experts have assisted clients across the industry, including brand and generic pharmaceutical companies, biotechnology companies, product manufacturers, healthcare providers, and insurers. We have performed analysis and testified in a variety of cases on issues including class certification, antitrust liability, antitrust damages, patent infringement, and product liability. In these contexts, Edgeworth experts have assessed economic and econometric issues in the pharmaceutical industry relating to:
- Pay for Delay
- Product Hopping
- Price Fixing
- Bid Rigging
- Exclusive Contracting
- Consumer Protection
- False Advertising
- Intellectual Property Damages
- Contract Disputes
- Business & Regulatory Consulting | 07.2022
- Litigation | 07.24.2019
- Litigation | 09.24.2014
Insights & News
- Published Article, Law360 | 05.16.2022
In this article, Dr. George Korenko and Dr. Tram Nguyen identify dimensions along which, over aggregation and averaging, likely lead to findings of uninjured class members.
- Published Article, Law360 | 07.21.2020
In this article, published in Law360, Edgeworth Partner Dr. George Korenko and Principal Consultant Dr. Tram Nguyen discuss three key issues cited in the Court of Appeals opinion and their implications for the economic analysis of predominance in the Lamictal case and in other pay-for-delay litigations.
- Blog, 09.06.2022
When pharmaceutical manufacturers develop a new branded drug to take to market, they are granted a period of exclusivity via patent to help recoup the massive costs of research and development. Upon expiration of this patent, generic manufacturers can enter the market with therapeutically equivalent products and compete with the brand.
- Navigating Antitrust Issues in the Pharmaceutical and Life Science Industries: Key Trends and Challenges ExploredEvent, 06.21.2022
A panel of distinguished thought leaders, including Edgeworth Principal Tram Nguyen, provide the audience with an in-depth discussion of the trends, developments, and critical issues surrounding pharmaceutical antitrust matters.
- Event, Antitrust Economics Workshop | Fordham Competition Law Institute | 10.07.2020
Edgeworth Economics will host the Antitrust Economics Workshop, to be held in advance of the 47th Annual Conference on International Antitrust Law
- Event, 01.10.2019
In this webcast, Dr. George Korenko will join other thought leaders to present on antitrust litigation and regulatory trends, their implications on the life sciences industry, and best practices for compliance.
- Press Release, 03.15.2023
Edgeworth Economics debuts The Antitrust Prescription, the firm’s new blog that covers antitrust and other economic issues affecting companies in the pharmaceutical industry.
The Antitrust Prescription
The Antitrust Prescription
- Blog, 11.29.2023
In the latest article for The Antritrust Prescription, Edgeworth Managing Principal Dr. Ashley Zhou examines recent enforcement concerning the listing of patents in the FDA's Orange Book and potential economic implications of new enforcement efforts.
- Blog, 07.26.2023
In this new article for The Antitrust Prescription, our pharmaceutical economics team discusses Amgen’s proposed acquisition of Horizon and the FTC’s broader approach to challenging conduct under Section 5 of the FTC Act.
- Blog, 05.30.2023
In this edition of The Antitrust Prescription, our Pharmaceutical Economics team discusses Merck and Glenmark's settlements with direct purchasers, end payors, and retailers worth over a combined $600 million.
- Blog, 03.15.2023
In this article, Dr. George Korenko and Dr. Tram Nguyen discuss a brief history of the numerosity standards and the potential implications of recent decisions in pharmaceutical antitrust matters.
Edgeworth has worked on numerous matters involving the economics of the pharmaceutical industry and drug pricing for both direct and indirect purchasers, including matters involving allegations of delayed generic entry, reverse payments, product-hopping, or other exclusionary practices. Representative matters include:
- In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
- In Re: Opana ER Antitrust Litigation
- In Re: Solodyn (Minocycline Hydrochloride) Antitrust Litigation
- In Re: Nexium (Esomeprazole) Antitrust Litigation
- In Re: Wellbutrin XL Antitrust Litigation